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In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that
early Ambroxol treatment (30 mg kg71 over the first 5 days) significantly reduces the incidence of RDS-associated
complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumo-
nia]. The aim of the present analysis was to investigate the eect of Ambroxol treatment on lung function in
newborns who developed BPD.
Respiratory function testing (RFT) was performed immediately after extubation and at day 28. Tidal volume
(VT) and respiratory frequency (f ) were measured during tidal breathing using the deadspace free flow-through
technique. The lung mechanic parameter VT/maxPes was determined by measuring the maximal oesophageal
pressure changes, maxPes, with a catheter tip pressure transducer.
In the placebo group 36/50 infants were extubated within the first 28 days of life and 13/36 (36%) developed
BPD. In the Ambroxol group 44/52 were extubated and 9/44 (20%) developed BPD. After extubation, RFT
showed (i) no statistically significant dierence in the ventilatory parameters of either treatment group, (ii)
improved (P5005) lung mechanics (VT/maxPes) in Ambroxol group compared to controls (94+27 ml kPa71 vs.
81+26 ml kPa71) and (iii) no statistically significant dierence in lung function between infants with and without
BPD. At day 28 we found (i) no eect of early Ambroxol treatment on lung functions, (ii) significantly (P5005)
higher f (585+117 min71 vs. 497+101 min71) and significantly (P5001) lower VT (96+19 ml vs. 123+27
ml) and VT/maxPes (89+26 ml kPa71 vs. 120+29 ml kPa71) in infants with BPD compared to infants without
and (iii) these dierences are not influenced by early Ambroxol treatment.
If the process of BPD development is induced, early Ambroxol treatment has no influence on impaired lung
function at day 28.
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Ambroxol, a metabolite of bromhexine with a high anity
for lung tissue (1), is well established in the treatment of
respiratory disorders of dierent aetiology. Ambroxol’s
most important pharmacological activity is mucokinetic1This work was supported by the German Ministry for Research
and Technology, project ‘‘Perinatal Lung’’ (grant 01 ZZ 9511).
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0954-6111/00/040378+07 $35?00/0and secretolytic, it stimulates synthesis and release of
surfactant from type II pneumocytes, and has anti-
oxidative and anti-inflammatory eects (2–4). The anti-
oxidative function of Ambroxol has been studied in detail
in in vitro investigations by Nowak et al. (5) in cell-free
suspensions, and by Gillissen et al. (6) using mononuclear
and polymorphonuclear cells.
A large number of preclinical and clinical studies have
been performed to investigate the influence of prenatal or
postnatal Ambroxol treatment on lung maturation [over-
view in (1)]. The results from these studies, however, are
inconsistent with regard to the eect of Ambroxol on lung
function in the developing lung (7,8).
In our previously published clinical trial (9) in preterm
newborns51500 g, the eect of early Ambroxol treatment
on the course of the respiratory distress syndrome (RDS)# 2000 HARCOURT PUBLISHERS LTD
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this study were that at day 28 the degree of respiratory
support in the Ambroxol group was reduced and the
incidence of bronchopulmonary dysplasia (BPD), intraven-
tricular haemorrhage (IVH) and postnatal acquired pneu-
monia was significantly lower as compared to the control
group. No adverse events were seen which could be
attributed to the Ambroxol treatment.
In ventilated very low birth weight (VLBW) newborns,
the BPD remains the most common pulmonary sequelae in
survivors with an incidence of 20–50% depending on the
definition used for characterization of BPD (10). The main
factors contributing to the development of BPD are
structural and functional immaturity (11), volotrauma
(12), hyperoxia (13) and infections (14).
In view of its known qualities it was anticipated that early
Ambroxol treatment would reduce the incidence of BPD at
day 28 and also the degree of the lung function disorders in
infants who developed BPD. Therefore, the aim of the
present analysis was to investigate the eect of the early
Ambroxol treatment on lung function by means of
respiratory function testing (RFT) immediately after
extubation and at day 28 in infants who fulfilled criteria
of BPD (15).
Materials and methods
The clinical trial was a double-blind parallel group
comparison, carried out in the neonatal units of the
Humboldt University, Berlin, and the Technical University,
Dresden. The clinical trial was reviewed and approved by
the Ethics Committees of both hospitals, and informed
consent was obtained from parents before randomization.
PATIENT MANAGEMENT
According to the estimated sample size (9), 102 preterm
newborns with RDS who had survived day 28 were enrolled
in the study. All newborns required mechanical ventilation
during the first days of life because of severe respiratory
insuciency. Admission criteria were: (i) birthweight
51500 g and a gestational age of 5 34 weeks; (ii)
radiological findings consistent with RDS (grading accord-
ing to Bomsel (16)); (iii) a need for mechanical ventilation
and (iv) a need for FIO2404 to maintain a PaO2465 kPa
(50 mmHg). Exclusion criteria were (i) positive blood
cultures in the umbilical cord blood samples at birth; (ii)
major malformations detected after enrolment and (iii)
incomplete study protocol. In accordance with the rando-
mized assignment, 52 preterm infants received 30 mg kg71
bodyweight Ambroxol (Mucosolvan, Dr Karl Thomae
Ltd., Biberach) per day during the first 5 days of life and
50 infants received placebo (physiological saline). A blinded
vial contained either 2 ml of saline or 15 mg Ambroxol
diluted in 2 ml saline. The total daily dose was divided into
four individual doses of 75 mg kg71 and was given as
infusion over 5 min every 6 h. No other drugs to improve
gas exchange were administered.RESPIRATORY FUNCTION TESTING
An important consideration in RFT in clinical trials is the
choice of suitable tests and devices. In newborns the non-
invasive single-breath occlusion technique is commonly
used for measurements of lung mechanics. However, this
test depends on several requirements (17) e.g. description of
lung mechanics using a one compartment model, sucient
Herring–Breuer reflex, sucient occlusion time for intra-
alveolar pressure equilibration which cannot be taken for
granted in the enrolled patients. To ensure data inclusion, a
robust method of data capture was used based on a
combination of flow-though technique (FTT) and oeso-
phageal manometry.
Measurements of ventilation and lung mechanics were
performed at the bedside during tidal breathing as
described previously (18) using custom-made equipment.
We used a face chamber (FC-100, Siemens-Elema, Sweden)
with latex cus that could be altered in line with the body
weight for optimal adaptation on the face. The face
chamber was continuously rinsed thoroughly with a back-
ground flow (V’const). This almost completely eliminated the
apparatus dead space and enabled long-term measurements
to be taken, even in oxygen-dependent newborns. Flows in
and out of the chamber were measured by two screen
pneumotachographs (Jaeger, Wu¨rzburg, Germany) and the
infant’s air flow was the dierence between the two signals.
To assess lung mechanics, oesophageal pressure changes
were measured using a catheter tip pressure transducer
(Messgeraete Werk Zwoentiz, Germany) with a catheter
diameter of 14 mm and a pressure transducer diameter of
17 mm at the tip. The catheter was placed in the lower third
of the oesophagus in the area of the largest pressure
changes. The placement was guided by the volume and
pressure signals which were monitored simultaneously. The
catheter was passed through the oral cavity downwards to
the stomach. A rise in pressure on inspiration confirmed
appropriate placement (Fig. 1). The catheter was then
drawn back into the oesophagus up to the region of
maximal pressure changes and minimal disturbances (e.g.
heart activity). The infant was placed supine with the neck
in the natural position. They were kept dry and clean and
no sedatives were used. RFT was performed about 30 min
after feeding. The FIO2 of the background flow was
adjusted in accordance with therapeutic requirements.
The expiratory background flow was always higher than
the peak tidal inspiratory flow (19). Calibration of the
volume was carried out with the breathing gas used for the
measurements.
Following optimal placement of the oesophageal cathe-
ter, the infants were allowed to adapt for 5–20 min. The
adaptation period is commonly characterized by an initially
high variability of the signals and high respiratory
frequency. During this adaptation period the respiratory
frequency decreases and steady state is reached, charcter-
ized by low respiratory frequency and a more regular
breathing pattern.
Depending on the variability of signals, 5–10 artefact-free
breathing cycles were evaluated and tidal volume (VT),
respiratory frequency (f) and maximal oesophageal pressure
FIG. 1. Course of oesophageal pressure changes (top), air flow rate (middle) and volume (bottom) by placement of the
catheter tip transducer in the stomach (on the left, visible by the rise in pressure at beginning of inspiration), and in the lower
third of the oesophagus (on the right) with a clear decrease in pressure on inspiration.
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mechanic parameter (VT/maxPes). This parameter mainly
describes the elastic properties of the lung and is
independent from any assumption about lung mechanics
(e.g. linear one-compartment model) (18).
STATISTICAL METHODS
Contingency tables were used to analyse qualitative
parameters. The statistical significance was evaluated using
the chi squared test or the Fisher exact test (one-tailed) if
the cell frequencies in the two by two tables were smaller
than five.
For quantitative data, mean and standard deviation (SD)
or standard error mean (SEM) were calculated and for their
comparison the two-tailed Students t-test was used,
provided the data were distributed parametrically.
All pulmonary parameters are presented as arithmetic
group means with SD in the text and as mean with
95% confidence intervals in the figures. For non-
parametric data (e.g. duration of mechanical ventilation),
median and range were used and the dierences between
groups were investigated using rank tests (Wilcoxon,
Mann–Whitney). For statistical evaluation the software
STATGRAPHICS (Vers. 3.0, Manugistics Inc., U.S.A.)
was used. A level of statistical significance of P5005 was
accepted.Results
In the placebo group, 36/50 (72%) infants could be
extubated within the first 28 days of life and 13/36 (36%)
developed BPD. Simultaneously in the Ambroxol group the
number of extubated infants was 44/52 (81%), and 9/44
(20%) developed BPD. As shown in Table 1 in both
treatment groups essential patient characteristics influen-
cing the clinical outcome did not dier significantly between
the infants with and without BPD, except for the lower
gestational age and the higher duration of mechanical
ventilation in placebo-treated infants who developed BPD.
RFT AFTER EXTUBATION
Immediately after extubation, respiratory frequency (Fig. 2)
and tidal volume (Fig. 3) did not dier significantly between
either treatment group and their BPD subgroups. However,
in infants treated with Ambroxol, the lung mechanics were
slightly improved (pooled data of BPD and non-BPD
infants) and the quotient VT/maxPes (Fig. 4) was signifi-
cantly higher (P5005) compared to infants treated with
placebo. With regard to clinical outcome, in neither
treatment group were there statistically significant dier-
ences in lung function between infants with and without
BPD at day 28.
TABLE 1. Characteristics of the investigated patients of both treatment groups with and without BPD at day 28 (mean+ SD or
median and range)
Placebo group
n  36
Ambroxol group
n  44
without BPD BPD P without BPD BPD P
Number of infants 23 (64%) 13 (36%) 35 (80%) 9 (20%)
Boys 10 (44%) 9 (69%) 017 19 (54%) 8 (89%) 012
Gestational age (weeks) 304+14 290+18 002 296+15 292+21 050
Birthweight (g) 1318+152 1194+239 007 1251+1211 1256+169 095
Body weight at day of extubation (g) 1332+241 1225+247 021 1257+208 1230+164 051
Body weight at day 28 (g) 1557+243 1378+324 007 1474+258 1399+169 042
Duration of mechanical ventilation (h)
median (range)
144 (70–524) 240 (159–552) 0002 158 (35–555) 188 (43–400) 072
FIG. 2. Respiratory frequency after extubation (left) and at day 28 (right). The group means with the 95% confidence
interval are presented. *P505, ***(P50001)=significant dierences compared to the measurements after extubation.
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Early Ambroxol treatment had no influence on late
respiratory function by day 28. Tidal volume (Fig. 3) was
increased in all groups (P50001) compared to the initial
measurements after extubation. The respiratory frequency
was also significantly decreased (P5005) in infants with-
out BPD, but unchanged in infants with BPD compared to
the results after extubation. VT/maxPes (Fig. 4) was only
significantly improved (P50001) in infants without BPD.In contrast to RFT after extubation, there were
significant dierences between infants with and without
BPD at day 28 all measured parameters and these
dierences were similar to those in infants with and without
Ambroxol treatment. Compared to infants without BPD at
day 28 in both treatment groups, the infants with BPD had
a significantly higher (P50001) respiratory frequency
(585+117 min71 vs. 497+101 min71), a significantly
lower (P50001) tidal volume (96+19 ml vs. 123+27 ml)
and VT/maxPes (89+26 ml kPa71 vs. 120+29 ml kPa71).
FIG. 4. The ratio VT/maxPes after extubation (left) and at day 28 (right). The group means with the 95% confidence interval
are presented. ***P50001=significant dierences compared to the measurements after extubation.
FIG. 3. Tidal volume after extubation (left) and at day 28 (right). The group means with the 95% confidence interval are
presented. ***P50001=significant dierences compared to the measurements after extubation.
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To investigate the eect of early Ambroxol treatment on
lung function in BPD infants, we have re-evaluated data of
our clinical trial (9) which was carried out in the former
GDR at a time when surfactant therapy was not available
and the pharmacological eect of the Ambroxol treatment
was not influenced by surfactant replacement. This study is
unique in the sense that in the future the eects of
Ambroxol will probably never again be investigated in this
group of untreated RDS patients since surfactant is
considered standard treatment for neonatal RDS.
The method of RFT used in this clinical trial (9) is
suitable to investigate lung function in VLBW infants (18).
Immediately after extubation, we found that Ambroxol
treatment had a moderate eect on lung mechanics, but
that this was not detectable by means of ventilatory
measurements. In a previous study (18) we showed that in
preterm mechanically ventilated newborns the ventilatory
parameters were mostly within the normal range after
extubation; therefore, large dierences between treatment
groups are not to be expected. Furthermore, in this study
by modelling an energetic optimal breathing pattern in
newborns with RDS we have shown that the sensitivity of
tidal breathing parameters is not suciently high to detect
small changes in lung mechanics.
In contrast to the first RFTs immediately after extuba-
tion, at day 28 there were significant dierences in lung
function between infants with and without BPD. In infants
with BPD, respiratory frequency was increased and tidal
volume reduced. These changes in the tidal breathing
pattern are probably caused by impaired lung mechanics,
apparent from the significantly reduced VT/maxPes. How-
ever, there is no measurable eect of early Ambroxol
treatment on the lung function at day 28.
As shown previously, early Ambroxol therapy reduces
the incidence of BPD in VLBW infants with established
RDS (9). We speculated that this decrease may have been
caused by a reduction of essential BPD risk factors i.e. a
reduction in supplemental oxygen, a shorter duration of
respiratory support and a lower incidence of infections. The
eect of this treatment is explained by an improved supply
of surfactant for alveoli and also by the anti-oxidative and
anti-inflammatory activities of Ambroxol (5,6).
However, as in early endotracheal surfactant substitu-
tion, in the present study, early Ambroxol treatment
showed no influence on lung function in infants with
BPD. Contrary to expectation, the introduction of surfac-
tant in the treatment of immature surfactant-deficient lungs
in VLBW infants failed to suciently decrease the incidence
of BPD (20–22). Rojas et al. (23) have shown that some of
the observed infants, with initially mild respiratory
disorders, developed a progressively increased respiratory
insuciency with need for mechanical ventilation. This
worsening in the clinical course may be caused by a second
inflammatory disease which develops beyond the first week
of life, independent of the initial postnatal cause of
respiratory failure (24,25). These results are in agreement
with the present study in which no significant dierence in
the lung function was found immediately after extubationin infants with and without BPD, whereas we found
significant dierences in all investigated respiratory para-
meters at day 28. We speculate that in infants who
developed BPD the progressive activity of late inflamma-
tory processes damages the lung tissue, leading to impaired
lung function at day 28. This may explain the main results
of this study, that early Ambroxol therapy reduces the
incidence of BPD but has no influence on inflammatory
processes beyond the first week of life which can lead to
BPD.
In the present study, Ambroxol was given over a period
of 5 days and a long-term eect cannot be expected.
Possibly, the deterioration of lung function in infants who
subsequently developed BPD could be reduced by pro-
longed Ambroxol treatment over a longer period. However,
no reports exist about such treatment in preterm infants.
The study has shown furthermore that the RFT is a
valuable tool for assessment of lung development provided
that the equipment is well adapted for measurements in
preterm infants.
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